利伐沙班上市日期

Rivaroxaban is also a drug used to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome. Today we will learn about the launch date of rivaroxaban.

Rivaroxaban marketing time: Rivaroxaban was approved for marketing in Canada and the European Union on September 15 and October 1, 2008 respectively. On July 1, 2011, the FDA approved the drug for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery. It was approved for marketing by the State Food and Drug Administration in March 2009, and was successfully included in the 2009 National Medical Insurance Catalog in the same year.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited. Rivaroxaban does not inhibit thrombin and has no proven effect on platelets. A dose-dependent inhibition of factor xa activity by rivaroxaban has been observed in humans.

The recommended dose is oral rivaroxaban 10 mg once daily. If the wound has stopped bleeding, the first medication should be administered between 6 and 10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone. For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a dose is missed, the patient should take rivaroxaban immediately and continue taking it once daily the next day. Patients can take rivaroxaban with a meal or on its own.

In addition, things to note about rivaroxaban are: 1. Patients with liver and renal insufficiency can significantly increase the blood concentration of this product, leading to an increased risk of bleeding. 2. Patients with active bleeding; patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks; 3. Contraindicated in pregnant and lactating women. 

The above is the content of rivaroxaban on the market, I hope it can help you!